vs
Side-by-side financial comparison of Elanco Animal Health Inc (ELAN) and LANDSTAR SYSTEM INC (LSTR). Click either name above to swap in a different company.
LANDSTAR SYSTEM INC is the larger business by last-quarter revenue ($1.2B vs $1.1B, roughly 1.0× Elanco Animal Health Inc). LANDSTAR SYSTEM INC runs the higher net margin — 3.4% vs -24.1%, a 27.5% gap on every dollar of revenue. On growth, Elanco Animal Health Inc posted the faster year-over-year revenue change (12.2% vs 1.6%). Over the past eight quarters, LANDSTAR SYSTEM INC's revenue compounded faster (-2.2% CAGR vs -2.6%).
Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
Landstar System, Inc. is an American transportation services company specializing in logistics and, more specifically, third-party logistics. Landstar utilizes an extensive network of over 8,800 independent owner-operators, referred to internally as business capacity owners (BCOs), over 1,000 independent freight agents, and over 70,000 vetted carriers. Landstar provides services principally throughout the United States and to a lesser extent in Canada and between the U.S. and Canada, Mexico, ...
ELAN vs LSTR — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $1.2B |
| Net Profit | $-276.0M | $39.4M |
| Gross Margin | 51.5% | 9.6% |
| Operating Margin | -22.6% | 4.5% |
| Net Margin | -24.1% | 3.4% |
| Revenue YoY | 12.2% | 1.6% |
| Net Profit YoY | -3350.0% | 32.3% |
| EPS (diluted) | $-0.55 | $1.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.1B | $1.2B | ||
| Q3 25 | $1.1B | $1.2B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | $1.2B | $1.2B | ||
| Q4 24 | $1.0B | $1.2B | ||
| Q3 24 | $1.0B | $1.2B | ||
| Q2 24 | $1.2B | $1.2B |
| Q1 26 | — | $39.4M | ||
| Q4 25 | $-276.0M | $23.9M | ||
| Q3 25 | $-34.0M | $19.4M | ||
| Q2 25 | $11.0M | $41.9M | ||
| Q1 25 | $67.0M | $29.8M | ||
| Q4 24 | $-8.0M | $46.2M | ||
| Q3 24 | $364.0M | $50.0M | ||
| Q2 24 | $-50.0M | $52.6M |
| Q1 26 | — | 9.6% | ||
| Q4 25 | 51.5% | — | ||
| Q3 25 | 53.4% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.3% | — | ||
| Q4 24 | 50.9% | — | ||
| Q3 24 | 52.2% | — | ||
| Q2 24 | 58.2% | — |
| Q1 26 | — | 4.5% | ||
| Q4 25 | -22.6% | 2.5% | ||
| Q3 25 | -4.4% | 2.2% | ||
| Q2 25 | 2.0% | 4.6% | ||
| Q1 25 | 5.0% | 3.4% | ||
| Q4 24 | -5.0% | 4.8% | ||
| Q3 24 | 54.3% | 5.2% | ||
| Q2 24 | -2.7% | 5.6% |
| Q1 26 | — | 3.4% | ||
| Q4 25 | -24.1% | 2.0% | ||
| Q3 25 | -3.0% | 1.6% | ||
| Q2 25 | 0.9% | 3.5% | ||
| Q1 25 | 5.6% | 2.6% | ||
| Q4 24 | -0.8% | 3.8% | ||
| Q3 24 | 35.3% | 4.1% | ||
| Q2 24 | -4.2% | 4.3% |
| Q1 26 | — | $1.16 | ||
| Q4 25 | $-0.55 | $0.70 | ||
| Q3 25 | $-0.07 | $0.56 | ||
| Q2 25 | $0.02 | $1.20 | ||
| Q1 25 | $0.13 | $0.85 | ||
| Q4 24 | $-0.01 | $1.30 | ||
| Q3 24 | $0.73 | $1.41 | ||
| Q2 24 | $-0.10 | $1.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $545.0M | $411.0M |
| Total DebtLower is stronger | $3.9B | $26.1M |
| Stockholders' EquityBook value | $6.5B | $799.0M |
| Total Assets | $13.4B | $1.6B |
| Debt / EquityLower = less leverage | 0.60× | 0.03× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $411.0M | ||
| Q4 25 | $545.0M | $452.2M | ||
| Q3 25 | $505.0M | $434.4M | ||
| Q2 25 | $539.0M | $426.2M | ||
| Q1 25 | $487.0M | $473.4M | ||
| Q4 24 | $468.0M | $566.6M | ||
| Q3 24 | $490.0M | $531.3M | ||
| Q2 24 | $416.0M | $504.0M |
| Q1 26 | — | $26.1M | ||
| Q4 25 | $3.9B | $0 | ||
| Q3 25 | $4.0B | $0 | ||
| Q2 25 | $4.1B | $0 | ||
| Q1 25 | $4.4B | $0 | ||
| Q4 24 | $4.3B | $0 | ||
| Q3 24 | $4.4B | $0 | ||
| Q2 24 | $5.7B | $0 |
| Q1 26 | — | $799.0M | ||
| Q4 25 | $6.5B | $795.7M | ||
| Q3 25 | $6.7B | $888.7M | ||
| Q2 25 | $6.8B | $921.8M | ||
| Q1 25 | $6.4B | $930.8M | ||
| Q4 24 | $6.1B | $972.4M | ||
| Q3 24 | $6.5B | $1.0B | ||
| Q2 24 | $5.9B | $1.0B |
| Q1 26 | — | $1.6B | ||
| Q4 25 | $13.4B | $1.6B | ||
| Q3 25 | $13.6B | $1.7B | ||
| Q2 25 | $13.7B | $1.7B | ||
| Q1 25 | $12.9B | $1.7B | ||
| Q4 24 | $12.6B | $1.8B | ||
| Q3 24 | $13.3B | $1.8B | ||
| Q2 24 | $13.8B | $1.8B |
| Q1 26 | — | 0.03× | ||
| Q4 25 | 0.60× | 0.00× | ||
| Q3 25 | 0.59× | 0.00× | ||
| Q2 25 | 0.61× | 0.00× | ||
| Q1 25 | 0.69× | 0.00× | ||
| Q4 24 | 0.70× | 0.00× | ||
| Q3 24 | 0.67× | 0.00× | ||
| Q2 24 | 0.96× | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $108.0M | — |
| Free Cash FlowOCF − Capex | $46.0M | — |
| FCF MarginFCF / Revenue | 4.0% | — |
| Capex IntensityCapex / Revenue | 5.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $284.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $108.0M | $72.7M | ||
| Q3 25 | $219.0M | $89.3M | ||
| Q2 25 | $237.0M | $7.1M | ||
| Q1 25 | $-4.0M | $55.7M | ||
| Q4 24 | $177.0M | $61.1M | ||
| Q3 24 | $162.0M | $83.1M | ||
| Q2 24 | $200.0M | $48.1M |
| Q1 26 | — | — | ||
| Q4 25 | $46.0M | $70.5M | ||
| Q3 25 | $127.0M | $86.0M | ||
| Q2 25 | $180.0M | $4.7M | ||
| Q1 25 | $-69.0M | $53.8M | ||
| Q4 24 | $130.0M | $54.4M | ||
| Q3 24 | $120.0M | $75.6M | ||
| Q2 24 | $166.0M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | 4.0% | 6.0% | ||
| Q3 25 | 11.2% | 7.1% | ||
| Q2 25 | 14.5% | 0.4% | ||
| Q1 25 | -5.8% | 4.7% | ||
| Q4 24 | 12.7% | 4.5% | ||
| Q3 24 | 11.7% | 6.2% | ||
| Q2 24 | 14.0% | 3.3% |
| Q1 26 | — | — | ||
| Q4 25 | 5.4% | 0.2% | ||
| Q3 25 | 8.1% | 0.3% | ||
| Q2 25 | 4.6% | 0.2% | ||
| Q1 25 | 5.4% | 0.2% | ||
| Q4 24 | 4.6% | 0.6% | ||
| Q3 24 | 4.1% | 0.6% | ||
| Q2 24 | 2.9% | 0.6% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.04× | ||
| Q3 25 | — | 4.61× | ||
| Q2 25 | 21.55× | 0.17× | ||
| Q1 25 | -0.06× | 1.87× | ||
| Q4 24 | — | 1.32× | ||
| Q3 24 | 0.45× | 1.66× | ||
| Q2 24 | — | 0.91× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
LSTR
Segment breakdown not available.
